Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company focused on monoclonal antibody therapies for serious viral infectious diseases, beginning with SARS-CoV-2. The Invivyd news feed on Stock Titan highlights company announcements about clinical development, regulatory milestones, commercial performance, financing activities, and pipeline expansion.
Recent Invivyd news has featured updates on PEMGARDA (pemivibart), the company’s investigational monoclonal antibody authorized under a U.S. FDA emergency use authorization for pre-exposure prophylaxis of COVID-19 in certain immunocompromised adults and adolescents. The company reports quarterly PEMGARDA net product revenue and discusses uptake among healthcare providers caring for immunocompromised patients.
Investors also see frequent coverage of VYD2311, Invivyd’s vaccine-alternative monoclonal antibody candidate for COVID-19. News items describe FDA Fast Track designation, U.S. IND clearance, and the design of the Phase 3 DECLARATION trial within the broader REVOLUTION clinical program. Articles outline trial endpoints, intramuscular dosing regimens, and plans for pivotal data to support a potential Biologics License Application.
Beyond COVID-19, Invivyd’s news flow includes pipeline developments such as the selection of VBY329, a monoclonal antibody candidate for prevention of RSV infections in neonates, infants, and children, and discovery efforts targeting measles and other infectious diseases. Corporate news covers public offerings of common stock and pre-funded warrants, participation in healthcare conferences, and formation of the SPEAR Study Group to evaluate monoclonal antibody therapy for Long COVID and COVID-19 post-vaccination syndrome.
By following the IVVD news page, readers can review Invivyd’s official press releases and related updates in one place, including earnings announcements, clinical trial progress, regulatory designations, and capital-raising transactions.
Invivyd, Inc. (Nasdaq: IVVD) has announced key management changes effective December 16, 2022. Jeremy Gowler has been appointed as the Chief Operating and Commercial Officer, bringing 20 years of biopharma experience, including leadership at Sandoz. Additionally, Pete Schmidt, previously Vice President of Clinical Research, has been promoted to Chief Medical Officer. The company aims to advance its monoclonal antibodies pipeline for COVID-19 and other respiratory diseases while streamlining operations following Dr. Ellie Hershberger's departure, who will provide consulting services.
Invivyd, a clinical-stage biopharmaceutical company (Nasdaq: IVVD), has announced a strategic partnership with Population Health Partners (PHP) aimed at improving the efficiency of its NVD200 clinical program and developing engineered antibodies for COVID-19. This collaboration will leverage PHP's expertise in clinical development and regulatory strategies, aligning Invivyd's capabilities with the evolving SARS-CoV-2 landscape.
Invivyd's NVD200 candidate, integrating adintrevimab, is set to enter clinical trials in Q1 2023, addressing the urgent need for effective treatments amid dwindling antibody effectiveness against emerging variants.
Invivyd (Nasdaq: IVVD) announced its third-quarter 2022 results, highlighting a cash position of $419 million, expected to fund operations into Q2 2024. The company aims to advance its monoclonal antibody candidate, NVD200, into clinical trials in Q1 2023. During the quarter, R&D expenses decreased to $34.1 million from $49.4 million in 2021, while SG&A expenses rose to $13.2 million. The net loss narrowed to $45.1 million from $60.4 million year-over-year, with a per-share loss of $0.42. A conference call is scheduled for November 10 at 4:30 p.m. ET.
Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical firm, announced that CEO David Hering will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2022, at 4:25 p.m. GMT. The event will be accessible via a live webcast on the investor section of Invivyd’s website, with an archive available for 90 days post-presentation.
Invivyd focuses on developing antibodies to enhance immunity against serious viral respiratory diseases, including COVID-19. Its first candidate, NVD200, aims to prevent and treat COVID-19 using advanced antibody technology.
Invivyd, a clinical-stage biopharmaceutical company, announced a conference call to discuss its Q3 financial results on November 10, 2022, at 4:30 p.m. ET. The earnings report will cover the period ending September 30, 2022, alongside recent business highlights. Invivyd focuses on developing antibodies to combat viral respiratory diseases, notably COVID-19, with its candidate NVD200 showing promise. The company aims to enhance immunity against evolving viral threats. Analysts can join the Q&A session after the call.
Invivyd, Inc. (Nasdaq: IVVD) has appointed Christine Lindenboom, former senior vice president at Alnylam Pharmaceuticals, to its board of directors. Her extensive experience in healthcare and biopharmaceuticals is expected to enhance the company's strategic direction. Meanwhile, Redonda Miller, president of The Johns Hopkins Hospital, has stepped down from the board. Invivyd is focused on developing antibody solutions for viral diseases including COVID-19, with their first product, NVD200, anticipated to enter clinical trials in Q1 2023.
Invivyd (Nasdaq: IVVD) announced the appointment of Fred Driscoll as interim CFO, as part of a strategic restructuring to enhance capital efficiency and focus on key programs. The company is reallocating resources to support its integrated discovery platform and advance pipeline programs, particularly NVD200 for COVID-19 prevention and treatment. This transition follows the departure of Jane Pritchett Henderson and Eric Kimble, who are leaving to pursue other opportunities. An executive search for a permanent CFO and a business development executive is underway.
Invivyd (Nasdaq: IVVD) announced four poster presentations at ID Week 2022, showcasing findings from studies on adintrevimab. Key posters include:
- Poster 226: Higher Doses of Adintrevimab for COVID-19 treatment - Phase 1 preliminary results.
- Poster 591: Population Pharmacokinetics of Adintrevimab in clinical study participants.
- Poster 1113: Clinical outcomes with Early Adintrevimab Therapy in COVID-19.
- Poster 1132: Characterizing Viral Dynamics after Adintrevimab administration.
Adintrevimab remains investigational, showing promise against COVID-19 variants.
Invivyd, formerly Adagio Therapeutics, has generated multiple candidate antibodies for COVID-19 prevention and treatment. Their integrated discovery platform has produced NVD200, a novel combination of two monoclonal antibodies, set to enter clinical trials in Q1 2023. These antibodies show broad in vitro neutralization against a range of SARS-CoV-2 variants, including Omicron sublineages and SARS-CoV-1. Invivyd aims to provide enhanced protection from serious viral diseases through innovative antibody engineering, targeting non-overlapping epitopes to reduce immune pressure.
Invivyd, formerly Adagio Therapeutics, announced a name change reflecting its focus on developing anti-viral antibodies that enhance immunity against viral diseases, starting with COVID-19. The company will trade under the new ticker symbol IVVD on Nasdaq starting September 13, 2022. Invivyd aims to deliver effective antibody solutions through its advanced discovery platform, which integrates evolutionary virology and antibody engineering. Additionally, the company is working on multiple candidates for seasonal influenza prevention.
FAQ
What is the current stock price of Invivyd (IVVD)?
What is the market cap of Invivyd (IVVD)?
